Providing American firms faster access to the European Health Market
Kalms Consulting is pleased to announce that it is opening two new American offices in the most vibrant healthcare technology regions of the United States: San Francisco and Minneapolis.
Navigating FDA approval can be a significant investment in time and dollars. Executing a dual pathway strategy via the European market can provide a streamlined opportunity that quickly allows manufacturers to jumpstart revenue gains, develop a strong health economics story, and aggregate additional clinical data needed to successfully gain approval in the U.S. The European market is also an attractive target for well-established companies looking to expand beyond their native country.
Kalms Consulting enjoys longstanding relationships with small, mid-cap and large, US-based medical device, biotech, biopharma and life science clients who continue to benefit from broadening their revenue pathways in Europe. Establishing permanent offices in the United States to better serve existing and future clients made perfect sense. The Kalms Consulting team is comprised of experienced and highly qualified experts who deliver affordable, data-driven solutions to clients worldwide. The U.S. division will specifically focus its efforts on market access, strategic business development, technology assessment and market analysis while working in concert with their European counterparts.
Published on: March 24, 2018
